<div class="headers"><div>Figure 2. Change in radiographic progression by modified Sharp/van der Heijde score from baseline to week 54 in the ASPIRE trial, by tertile of week-14 28-joint Disease Activity Scores (DAS28). * = P <0.05; $ = P < 0.001, versus the MTX plus placebo group. Inflx = infliximab (see Figure 1 for other definitions and explanation of treatment groups).</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 2. Change in radiographic progression by modified Sharp/van der Heijde score from baseline to week 54 in the ASPIRE trial, by tertile of week-14 28-joint Disease Activity Scores (DAS28). </p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">* = P <0.05; $ = P < 0.001, versus the MTX plus placebo group. Inflx = infliximab (see Figure 1 for other definitions and explanation of treatment groups).</p></td>
</tr>
</tbody>
</table>
